Combination of Calcipotriene 0.05% Foam and Halobetasol Propionate 0.05% Foam in the Treatment of Scalp Psoriasis

Main Article Content

A Young
R Schreiber


Psoriasis, Calcipotriene, Halobetasol


Abstract not available.


1. National Psoriasis Foundation. (2019, July 31). About Psoriasis. Retrieved from Psoriasis.Org:
2. American Academy of Dermatology. (n.d.). Psoriasis clinical guideline. Retrieved December 24, 2019, from
3. Gudjonsson, J. E., & Elder , J. T. (2019). Chapter 28: Psoriasis. In S. Kang, M. Amagai, A. L. Bruckner, & et al (Eds.), Fitzpatrick's Dermatology (9 ed.). New York, NY: McGraw Hill.
4. Mayne Pharma. (2019, May14). SORILUX Prescribing Information. Greenville, NC.
5. Mayne Pharma. (2019, April). Halobetasol Foam, 0.05% Prescribing Information. Greenville, NC.
6. Mayne Pharma. (2019). Data on file.
7. Van de Kerkhof, P. C. (2001). Therapeutic strategies: Rotational therapy and combinations. Clin Exp Dermatol, 26, 356.
8. Stein Gold, L., Horgan,A., Schreiber, R., & Ye, R. (2019). Determination of the In Vitro Chemical Compatibility of Calcipotriene Foam, 0.005%, in Combination with Halobetasol ProprionateFoam, 0.05%. Winter Clinical Dermatology Conference. Kawaii, HI: FRED.